Phase 3 N=154 APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
MDS
Primary: Complete Response Rate (CR) — 27; 17 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=374 Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Attention-Deficit/Hyperactivity Disorder (ADHD)
Primary: Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score…
Phase 3 N=21 A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1
Primary Hyperoxaluria Type 1 · Primary Hyperoxaluria
Primary: Cohort A: Percent Change in Plasma Oxalate From Baseline to Month 6 — -33.33 percent change
Phase 3 N=460 A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer
Gastric Cancer · Gastric Adenocarcinoma
Primary: Overall Survival (OS) — 5.82; 5.13 Months
Phase 3 N=727 Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
Atopic Dermatitis
Primary: Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 — 48.2…
Phase 3 N=1,796 Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination With 20vPnC — 6.3; 7.4; 4.0; 3.3 Percentage of participants
Phase 3 N=263 Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
Rosacea
Primary: Efficacy Absolute Change in Inflammatory Lesion Count — -19.8; -20.9 Lesions — p=0.799
Phase 3 N=307 Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
Rosacea
Primary: Number of Subjects With 1 or More Treatment-related Treatment-Emergent Adverse Events — 48 participants
Phase 3 N=931 A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Crohn's Disease
Primary: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission — 24.6; 45.2; 41.6 percentage of participants — p=<0.001
Phase 3 N=882 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Triple Negative Breast Cancer (TNBC)
Primary: Part 1: Percentage of Participants Who Experienced an Adverse Event (AE) - All Participants — 100.0; 100.0; 100.0 Percentage of Participants
Phase 3 N=78 ESP Block VS TAP in Laparoscopic Hysterectomy
Hysterectomy
Primary: Visual Analogue Scale (VAS) Pain Scores at Rest at 1 Hour. — 2.8; 3 score on a scale
Phase 3 N=1,645 A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis
Atopic Dermatitis
Primary: Responder and Partial Responders (RPR): Percentage of Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved a Response of Investigator's Global Assessment…
Phase 3 N=154 A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
Type 2 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26 — 0.5; -0.7 percentage of HbA1C — p=<0.001
Phase 3 N=493 Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)
HIV Infections
Primary: Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) >=50 Copies/Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Category at Week 48 — 1…
Phase 3 N=1,302 A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Ulcerative Colitis (UC)
Primary: Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 — 0; 8.5; 14.3; 13.5 percentage of participants — p=0.049